Genomic sequencing analysis of 733 HER2-amplified Major and metastatic breast tumours exposed substantial enrichment of mutations that activate RAS–MAPK signalling in Sophisticated tumours addressed with prior anti-HER2 therapies121. These mutations, including NF1 and HER2 activating mutations, contribute to resistance to tucatinib and neratinib. They’ll question about your own and fa... https://www.directivepublications.org/journal-of-clinical-breast-cancer/